Kazia Therapeutics Limited
NASDAQ Capital MarketTotal Valuation
Kazia Therapeutics Limited carries a market capitalization of 17.74M, placing it among publicly traded companies globally. Its enterprise value stands at 8.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 17.74M |
| Enterprise Value | 8.97M |
Share Statistics
Kazia Therapeutics Limited currently has 9.76M shares outstanding.
| Shares Outstanding | 9.76M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.89, and the price-to-book ratio stands at -0.24.
| PE Ratio | N/A |
| PS Ratio | 2.89 |
| PB Ratio | -0.24 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 0.68 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Kazia Therapeutics Limited maintains a current ratio of 5.80, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.80 |
| Quick Ratio | 5.33 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -45.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 1,140.45 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kazia Therapeutics Limited's stock has gained approximately 128.60125% over the past 52 weeks. The 50-day moving average sits at 11.11, while the 200-day moving average is 8.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | 128.60125% |
| 50-Day Moving Average | 11.11 |
| 200-Day Moving Average | 8.61 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kazia Therapeutics Limited generated 13.27M in revenue and converted that into -21.46M in net income, yielding earnings per share of -1,101.69. EBITDA reached -35.93M, while operating income came in at -35.93M.
| Revenue | 13.27M |
| Gross Profit | N/A |
| Operating Income | -35.93M |
| Pretax Income | -5.87M |
| Net Income | -21.46M |
| EBITDA | -35.93M |
| EBIT | -35.93M |
| Earnings Per Share (EPS) | -1,101.69 |
Balance Sheet
Total book value stands at -162.16M, with working capital of 35.43M providing operational flexibility.
| Cash & Cash Equivalents | 34.36M |
| Total Debt | N/A |
| Net Debt | -27.99M |
| Equity (Book Value) | -162.16M |
| Book Value Per Share | -8,324.76 |
| Working Capital | 35.43M |
Margins
Kazia Therapeutics Limited operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -270.76 and net profit margin of -161.73 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -270.76 |
| Pretax Margin | -44.22 |
| Profit Margin | -161.73 |
| EBITDA Margin | -270.76 |
Stock Splits
Kazia Therapeutics Limited's most recent stock split took place on April 17, 2025 with a 5:1 split ratio.
| Last Split Date | 4/17/2025 |
| Split Ratio | 5:1 |
Scores
Kazia Therapeutics Limited posts an Altman Z-Score of -3.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.71 |